SARASOTA, FL -- (MARKET WIRE) -- 01/31/2006 -- DNAPrint Genomics, Inc. (OTC BB: DNAG) today announced the expansion of the Company's high-throughput genotyping capacity from 1.3 million to more than 3.9 million genotypes per day.

"Multiplexing and advanced automation protocols provide the flexibility to process large or small genotyping studies without compromising cost per genotype," stated DNAPrint Genomics President and Chief Executive Officer Richard Gabriel. "Increasing high-volume throughput advances our ability to determine genotypes at economical costs to our customers and business partners. Coupled with our population ancestry technology, we can achieve better research results at a business-smart price."

The increase in processing capacity particularly targets the pharmaceuticals and healthcare market. It enables the Company to process clinical trials samples to ensure that patient population groups are accurately categorized, and perform large scale genotyping work for the various industries interested.

DNAPrint Genomics Founder and Chief Scientific Officer Tony N. Frudakis, Ph.D., noted that the Company has key advantages over other laboratories offering genotyping services. "We are unique in our expertise in population structure analysis using our Ancestry Informative Markers (AIM)," said Dr. Frudakis. "We can demonstrate to our customers that failure to understand the ancestral or biological structure of their study population can significantly confound and even compromise genetic studies. We offer a unique approach to maximizing the probability of success in pharmacogenetic, predisposition, risk profiling and susceptibility studies that many companies are pursuing alongside drug and diagnostics development."

DNAPrint has genotyping facilities at its Sarasota headquarters and at laboratories in Richmond, Calif., and Toronto, Canada, which utilize sophisticated equipment manufactured by Beckman Coulter and Illumina, Inc. The U.S. laboratories are genotyping with the ultra sensitive and robust GenomeLab SNPstream from Beckman Coulter while the Toronto lab is equipped with the Illumina bead machine and is also offering HAP MAP SNP genotyping services.

"Results from the GenomeLab SNPstream from Beckman Coulter are 99+% reproducible, providing the kind of validation that we believe the U.S. Food and Drug Administration (FDA) is seeking for its clinical trials data," Dr. Frudakis noted.

About DNAPrint Genomics, Inc.

DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Pre-clinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to better design actual trials and are targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS™, RETINOME™, ANCESTRYbyDNA™ and EURO-DNA™. Recently announced and as a part of the Company's Trace Genetics acquisition, DNAWitness-Y and DNAWitness-Mito are two new tests that can be used as an identification tool when other DNA testing either fails to yield results or the sample might be too deteriorated.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation, to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

Company Contact:
Richard Gabriel
CEO and President
941 366-3400
-or-
Ron Stabiner
The Wall Street Group, Inc.
212-888-4848